Bone Metastases Clinical Trial
Official title:
A Feasibility Study to Evaluate the Safety and Initial Effectiveness of ExAblate MR Guided Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System
A study to evaluate the safety and initial effectiveness of the ExAblate 2100 Conformal Bone System in the treatment of pain resulting from metastatic bone tumors.
Bone is the third most common organ involved by metastatic disease behind lung and liver [6].
In breast cancer, bone is the second most common site of metastatic spread, and 90% of
patients dying of breast cancer have bone metastasis. Breast and prostate cancer metastasize
to bone most frequently, which reflects the high incidence of both these tumors, as well as
their prolonged clinical courses. Post-cancer survival has increased with improvement in
early detection and treatments. As a consequence, the number of patients developing
metastatic bone disease during their lifetime has also increased.
Current treatments for patients with bone metastases are primarily palliative and include
localized therapies (radiation and surgery), systemic therapies (chemotherapy, hormonal
therapy, radiopharmaceutical, and bisphosphonates although the primary goal of the use of
these therapies are often to address the disease itself), and analgesics (opioids and
non-steroidal anti-inflammatory drugs). Recently, radiofrequency ablation has been tested as
a treatment option for bone metastases [8]. Currently, an off label use of Cryoablation
techniques are being tested as another alternative for bone Mets palliation. The main goals
of these treatments are improvement of quality of life and functional level. These goals can
be further described:
1. Pain relief
2. Preservation and restoration of function
3. Local tumor control
4. Skeletal stabilization
Treatment with external beam radiation therapy (EBRT) is the standard of care for patients
with localized bone pain, and results in the palliation of pain for many of these patients.
Twenty to 30% of patients treated with radiation therapy do not experience pain relief
[9-13]. Re-treatment rates are generally reported in the range of 10-25%. Many patients with
relapsed pain or poor response to initial radiation may be lost to follow up or may not be
referred back to oncologists for consideration of re-radiation. In addition to relapse and
re-treatment, there is an increased risk of pathologic fracture in the peri-radiation period.
The fracture rate reported in radiation studies is generally in the range of 1% to 8%. The
hyperemic response weakens the adjacent bone and increases the risk of spontaneous fracture.
Furthermore, patients who have recurrent pain at a site previously irradiated may not be
eligible for further radiation therapy secondary to limitations in normal tissue tolerance.
Hesitation on the part of physicians to use a larger dose may be related to increased
long-term toxicity. Larger radiation dose produces a greater risk of complications such as
fibrosis of normal soft tissue, which can cause a decrement in the quality of life in cases
of life expectancy longer than 6 months. There may also be a greater incidence of acute side
effects of nausea and vomiting if the treatment field includes the stomach. The percent of
patients experiencing vomiting following EBRT ranges from about 5% to 30%.
A palliative treatment for painful bone metastases that is non-invasive, without long-term
toxicity and having minimal complications would be a useful tool for treating physicians and
also a beneficial option for patients suffering from painful bone metastases. Results of
preliminary studies indicate that ExAblate treatment of painful bone metastases may be a
beneficial treatment option [14, 15]. The ExAblate system is a non-invasive thermal ablation
device used in the coagulation of various types of soft tissue. The ExAblate system has the
potential to achieve the first three of the four previously mentioned goals in the treatment
of bone tumors; namely pain relief, preservation and restoration of functional levels and
local tumor control [11]. The ExAblate system used in the present study is a technological
advance over the ExAblate 2000 fixed transducer system in terms of flexibility of use and
reduction of positioning related pain to the patients. The ExAblate system used in this study
conforms to the patient's body shape at the location of the bone mets location.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03986593 -
Cryoablation of Bone Metastases From Endocrine Tumors
|
N/A | |
Active, not recruiting |
NCT01996046 -
FDG PET/CT in Breast Cancer Bone Mets
|
||
Completed |
NCT01358539 -
Palliation: the Effect of Education on Pain
|
Phase 3 | |
Completed |
NCT00762346 -
Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis
|
Phase 4 | |
Terminated |
NCT00757757 -
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
|
Phase 1/Phase 2 | |
Completed |
NCT00420433 -
Bone Response in Metastatic Breast Cancer Involving Bones
|
N/A | |
Completed |
NCT02826382 -
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
|
Early Phase 1 | |
Terminated |
NCT05301062 -
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
|
||
Recruiting |
NCT06367491 -
National Database of Bone Metastases
|
||
Completed |
NCT03223727 -
Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
|
||
Completed |
NCT00830180 -
Open Label Extension In Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03305224 -
The Combination Therapy With Ra-223 and Enzalutamide
|
Phase 2 | |
Withdrawn |
NCT04109937 -
External Beam Radiation Therapy Post Surgery in Patients With Lower Extremity Bone Metastases Randomized Efficacy Trial
|
N/A | |
Active, not recruiting |
NCT02880943 -
Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)
|
Phase 1/Phase 2 | |
Completed |
NCT01696760 -
Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
|
N/A | |
Completed |
NCT00958477 -
A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer
|
Phase 1 | |
Completed |
NCT03979118 -
Exercise Prescription in Patients With Bone Metastases
|
||
Completed |
NCT03353090 -
Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients
|
N/A | |
Recruiting |
NCT05167669 -
Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU
|
Early Phase 1 | |
Recruiting |
NCT04568291 -
CTC in Lung Caner Patients With Bone Metastases
|
N/A |